The humanistic burden of hereditary angioedema: Results from the Burden of Illness Study in Europe

Allergy and Asthma Proceedings

Volumn 35, Issue 1, 2014, Pages 47-53

  Caballero, Teresa ^a   Aygören Pürsün, Emel ^b   Bygum, Anette ^c   Beusterien, Kathleen ^d   Hautamaki, Emily ^d   Sisic, Zlatko ^e   Wait, Suzanne ^f   Boysen, Henrik B ^g  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d ICON PLC   (United Kingdom)

^e ViroPharma Chatsworth House   (United Kingdom)

^f SHW Health Ltd   (United Kingdom)

^g HAEi International Patient Organization for C1 Inhibitor Deficiencies   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMEN; ADULT; ANGIONEUROTIC EDEMA; ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; EUROPE; FEMALE; HEALTH CARE QUALITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LIMB; MAJOR CLINICAL STUDY; MALE; PAIN; SWELLING; WELLBEING; ARTICLE; CHILD; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; EMOTIONALITY; HEALTH IMPACT ASSESSMENT; PAIN ASSESSMENT; PAIN INTENSITY; POPULATION RESEARCH; PSYCHOLOGICAL WELL-BEING; QUALITY OF LIFE; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY;

ACTIVITIES OF DAILY LIVING; ADULT; AGE OF ONSET; ANGIOEDEMAS, HEREDITARY; DENMARK; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SPAIN;

EID: 84987657462     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3685     Document Type: Conference Paper

References (32)

1. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine 71:206-215, 1992.
2. Frank MM, Gelfand JA, and Atkinson JP. Hereditary angioedema: The clinical syndrome and its management. Ann Intern Med 84:580-593, 1976.
3. Caballero T, Baeza ML, CabañasR, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 21:333-347, 2011.
4. Bork K, Meng G, Staubach P, and Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006.
5. Bygum A. Hereditary angio-oedema in Denmark: A nationwide survey. Br J Dermatol 161:1153-1158, 2009.
6. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
7. Bork K, Hardt J, Schicketanz KH, and Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229-1235, 2003.
8. Bork K, Hardt J, and Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692-697, 2012.
9. Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: Patient-based considerations. Allergy Asthma Proc 33:235-240, 2012.
10. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: Patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 94:498-503, 2005.
11. Agostoni A, Aygören-Pr̈sün E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:S51-S131, 2004.
12. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
13. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67:147-157, 2012.
14. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, followup, and special situations. J Investig Allergol Clin Immunol 21:422-441, 2011.
15. Erratum appears in J Investig Allergol Clin Immunol 22:3, 2012.
16. Craig T, Pü rsün EA, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5:182-199, 2012.
17. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 129:308-320, 2012.
18. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31:407-414, 2010.
19. Caballero T, Caminoa M, Prior N, et al. Health-related quality of life in adult patients with hereditary angioedema due to C1. inhibitor deficiency (HAE-C1-INH) assessed by SF-36v2: Preliminary results of an international study. Allergy: European Journal of Allergy and Clinical Immunology Conference, 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey Conference June 11-25, 2012.
20. Bygum A, Andersen KE, and Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19:147-151, 2009.
21. Kreuz W, Martinez-Saguer I, Aygören-Pü rsün E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 49:1987-1995, 2009.
22. Bewtra AK, Levy RJ, Jacobson KW, et al. C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life. Allergy Asthma Proc 33:427-431, 2012.
23. Bygum A, Aygören-Pü rsün E, Caballero T, et al. The hereditary angioedema burden of illness study in Europe (HAE-BOISEurope): Background and methodology. BMC Dermatol 12:4, 2012.
24. Zigmond AS, and Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983.
25. Olsson I, Mykletun A, and Dahl AA. The hospital anxiety and depression rating scale: A cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5:46, 2005.
26. Hinz A, and Brahler E. Normative values for the hospital anxiety and depression scale (HADS) in the general german population. J Psychosom Res 71:74-78, 2011.
27. Huang SW. Results of an on-line survey of patients with hereditary angioedema. Allergy Asthma Proc 25:127-131, 2004.
28. McAllister M, Davies L, Payne K, et al. The emotional effects of genetic diseases: Implications for clinical genetics. Am J Med Genet 143:15, 2007.
29. Freitag FG. The cycle of migraine: Patients' quality of life during and between migraine attacks. Clin Ther 29:939-949, 2007.
30. Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS ONE 8:e53773, 2013.
31. Dunn KM, Jordan K, Lacey RJ, et al. Patterns of consent in epidemiologic research: Evidence from over 25,000 responders. Am J Epidemiol 159:1087-1094, 2004.
32. Bernstein JA. HAE update: Epidemiology and burden of disease. Allergy Asthma Procs 34:3-6, 2013.